Edition:
United States

Mylan NV (MYL.O)

MYL.O on Nasdaq

18.34USD
23 Aug 2019
Change (% chg)

$-0.70 (-3.68%)
Prev Close
$19.04
Open
$18.89
Day's High
$19.10
Day's Low
$18.26
Volume
5,126,125
Avg. Vol
8,171,415
52-wk High
$39.59
52-wk Low
$16.63

About

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $20,534.19
Shares Outstanding(Mil.): 536.28
Dividend: --
Yield (%): --

Financials

  MYL.O Industry Sector
P/E (TTM): 31.22 29.89 32.67
EPS (TTM): 1.23 -- --
ROI: 2.39 14.89 14.48
ROE: 5.71 16.01 15.78

Denmark's Novo Nordisk files lawsuit against Mylan over patent

COPENHAGEN Novo Nordisk said on Thursday it has filed litigation in a Delaware district court against Mylan aimed at blocking its attempt to market a generic version of the Danish insulin maker's drug Victoza.

Aug 22 2019

Denmark's Novo Nordisk files lawsuit against Mylan over patent

COPENHAGEN, Aug 22 Novo Nordisk said on Thursday it has filed litigation in a Delaware district court against Mylan aimed at blocking its attempt to market a generic version of the Danish insulin maker's drug Victoza.

Aug 22 2019

Pfizer invests $500 million in expanding gene therapy facility

Pfizer Inc is investing $500 million to expand a manufacturing facility in Sanford, North Carolina, that plays a central role in its efforts to become a major player in gene therapy, the company said on Wednesday.

Aug 21 2019

Pfizer invests $500 million in expanding gene therapy facility

Aug 21 Pfizer Inc is investing $500 million to expand a manufacturing facility in Sanford, North Carolina, that plays a central role in its efforts to become a major player in gene therapy, the company said on Wednesday.

Aug 21 2019

Teva to launch generic version of EpiPen for young children

Aug 20 Teva Pharmaceutical Industries Ltd said on Tuesday its generic version of Mylan's EpiPen for young children will be available in most retail pharmacies at a price of $300 for a 2-pack.

Aug 20 2019

UPDATE 1-U.S. FDA approves TB Alliance's treatment for drug-resistant tuberculosis

Aug 14 The U.S. Food and Drug Administration has approved TB Alliance's treatment for drug-resistant tuberculosis as part of a three-drug combination regimen called BPaL, the not-for-profit said on Wednesday.

Aug 14 2019

U.S. lawmakers push Mylan, Teva over drug pricing probe

WASHINGTON The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

Aug 14 2019

UPDATE 3-U.S. lawmakers push Mylan, Teva over drug pricing probe

WASHINGTON, Aug 14 The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

Aug 14 2019

U.S. lawmakers push Mylan, Teva over drug pricing probe -statement

WASHINGTON, Aug 14 The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

Aug 14 2019

Fidelity battles IRS in court over coal tax credits

BOSTON Fidelity Investments' courtroom battle with the IRS over disallowed tax credits drew to a close on Tuesday when lawyers clashed over whether the mutual fund giant was a bonafide partner in the production of chemically treated coal.

Aug 13 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates